Key points are not available for this paper at this time.
Vemurafenib has an objective and sustained efficacy in BRAF(V600E)-mutated ECD as second-line therapy. In contrast to melanoma, no resistance has emerged to date after 6 to 16 months.
Haroche et al. (Tue,) studied this question.